Verona Pharma PLC 8-K filings

Verona Pharma plc has completed its acquisition by Merck Sharp & Dohme LLC, with shareholders receiving $13.375 per ordinary share or $107 per ADS, leading to its delisting from Nasdaq.

Verona Pharma plc shareholders have overwhelmingly approved the proposed $10 billion acquisition by Merck, moving the transaction closer to its expected October 7, 2025 closing.

Verona Pharma plc has amended its employee change in control severance plan, extending benefit periods and revising resignation terms, contingent on a pending transaction.

Merck announced its definitive agreement to acquire Verona Pharma for approximately $10 billion, adding Ohtuvayre, a recently FDA-approved first-in-class COPD treatment, to its growing cardio-pulmonary pipeline.

Verona Pharma announces a successful first quarter in 2025, driven by strong Ohtuvayre sales, exceeding operating expenses, and providing a corporate update.

Verona Pharma reports successful passage of all resolutions at its 2025 Annual General Meeting of Shareholders held on April 24, 2025.

Verona Pharma amends its strategic financing agreements, repurchasing the RIPSA and increasing its debt facility to $450 million with improved terms.

Verona Pharma announces positive Q4 and full-year 2024 results, driven by the successful launch of Ohtuvayre and progress in its Phase 2 clinical programs.

Verona Pharma announced a strong launch for its COPD drug Ohtuvayre, with approximately $36 million in net product sales for the fourth quarter of 2024 and $42 million for the full year.

Verona Pharma's Ohtuvayre launch sees $5.6 million in net sales in Q3 2024, with October sales exceeding Q3 results.

Verona Pharma announces the commercial availability of Ohtuvayre for COPD treatment in the US, alongside its second quarter 2024 financial results.

Verona Pharma's Ohtuvayre (ensifentrine) has been approved by the FDA for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

Verona Pharma reported its first quarter 2024 financial results, highlighted by a $650 million strategic financing and preparations for the potential launch of its COPD treatment, ensifentrine.

Verona Pharma has secured up to $650 million in non-dilutive financing through a debt facility and a revenue interest purchase agreement to support the commercial launch of ensifentrine and extend its cash runway beyond 2026.

Verona Pharma's shareholders passed all proposed resolutions at the 2024 Annual General Meeting, including the re-election of directors and approval of the annual accounts.

Verona Pharma reported its 2023 financial results, highlighted by a $400 million debt facility and preparations for the potential US launch of ensifentrine in the second half of 2024.

Verona Pharma has announced the resignation of a non-executive director and the appointment of a new non-executive director, effective January 31, 2024 and February 1, 2024 respectively.